Johnson & Johnson Rises on Blackstone Life Sciences Co-Funding Deal for AML Drug
Johnson & Johnson shares gained 1.40% to $245.88 after announcing a first-of-its-kind co-funding partnership with Blackstone Life Sciences. The collaboration accelerates clinical trials for bleximenib, an investigational menin-targeted therapy for acute myeloid leukemia (AML), a disease with limited treatment options.
The agreement establishes a joint financing model to support late-stage development, ensuring sustained funding through multiple trial phases. This structure allows both parties to share risk while streamlining resource allocation for faster progress.
J&J's oncology pipeline strengthens with the deal, which could set a precedent for future biopharma financing models. The market reaction reflects Optimism about the program's potential to address unmet needs in hematologic malignancies.
